Showing results for Cancer

IU School of Medicine researchers discover gamechanger combination drug for triple negative breast cancer

A team of Indiana University School of Medicine researchers has developed a novel antibody-drug conjugate for treating triple negative breast cancer.

IU School of Medicine | Feb 23, 2021

IU cancer center researchers discover how breast cancer cells hide from immune attack

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.

IU School of Medicine | Jan 26, 2021

IU cancer center findings could reduce treatment-related complication for blood cancer patients

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.

IU School of Medicine | Jan 07, 2021

IU School of Medicine researchers publish first scientific article dedicated to Tyler Trent’s donated tumors, his legacy

Researchers at Indiana University School of Medicine have published their work about a specific type of childhood cancer in the peer-reviewed, international oncology journal, Cancers. This research involves a combination therapy that significantly slows tumor growth in models, which includes a model established from cells taken from tumors donated by Tyler Trent.

IU School of Medicine | Dec 01, 2020

Harikrishna Nakshatri IU Simon Cancer Center

Cancer center researcher receives $1.3 million grant to improve breast cancer treatment for Black women

An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher is identifying the unique biology that may make Black women more susceptible to aggressive breast cancer.

IU School of Medicine | Nov 18, 2020

John Turchi National Cancer Institute grant lung cancer

IU researcher receives $2.9 million for work improving effectiveness in lung cancer radiation therapy

An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective.

IU School of Medicine | Nov 10, 2020

Walther bioinformatics grant Purdue IU Simon Cancer Center

Walther Cancer Foundation $11 million investment to expand IU-Purdue bioinformatics collaboration

The Walther Cancer Foundation will invest $11 million to advance collaborative cancer research at Indiana University and Purdue University by supporting scientists through bioinformatics — an increasingly critical aspect of their work.

IU School of Medicine | Oct 08, 2020

Kelvin Lee IU Simon Comprehensive Cancer Center

IU School of Medicine names new cancer center director, announces $15 million supporting gift from Walther Cancer Foundation

Indiana University School of Medicine has announced the hiring of a world-recognized medical oncologist and multiple myeloma researcher to lead the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, bolstered by a $15 million fund established by the Walther Cancer Foundation to support him in this role.

IU School of Medicine | Oct 07, 2020

Lois Travis, MD, IU Simon Cancer Center, oncology

IU cancer center researcher awarded $5.7 million to study chemo-induced hearing loss, toxicities

INDIANAPOLIS -- A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a five-year, $5.7 million National Cancer Institute grant to evaluate long-term health outcomes for cancer patients who receive platinum-based chemotherapies. An internationally recognized expert on cancer survivorship, Lois B. Travis, MD, ScD, leads the ongoing study that could lessen cancer treatment side effects for millions of patients.

IU School of Medicine | Sep 02, 2020

Bryan Schneider Milan Radovich triple negative breast cancer JAMA Oncology

IU School of Medicine findings set new standard for use of blood-based biomarkers in clinical trials for prediction of cancer recurrence

Indiana University School of Medicine researchers Milan Radovich, PhD, and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women’s blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival.

IU School of Medicine | Jul 09, 2020